| Black Pearl Group Limited (BPG) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Information Technology |
$77 |
Application for quotation of securities - BPG
|
26 Feb 2026 8:26AM |
$0.795 |
$0.795 |
fallen by
0%
|
|
| Oohmedia Limited (OML) ORDINARY FULLY PAID |
Communication Services |
$552 |
Announcement of on-market share buyback
|
26 Feb 2026 8:26AM |
$0.950 |
$1.025 |
risen by
7.89%
|
|
OML - Price-sensitive ASX Announcement
Full Release
Key Points
- oOh!media Limited announces on-market share buyback program.
- Buyback of up to 10% of issued share capital.
- Funded from existing cash and debt facilities.
- Buyback reflects confidence in strong growth trajectory and market conditions.
- Commences on or after 12 March 2026.
- Buyback seen as efficient use of capital due to undervaluation of shares.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,964 |
2025 Full Year Results Announcement
|
26 Feb 2026 8:25AM |
$4.840 |
$4.800 |
fallen by
0.83%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Proportional toll revenue grew by 9.4% in 2025.
- Proportional EBITDA reached $1,509.9 million.
- Statutory net profit after tax was $181.8 million, impacted by TST.
- Operating free cash flow per security was 34.9 cps.
- 2025 distribution guidance reaffirmed at 40.0 cps.
- New CEOs appointed at Dulles Greenway and Chicago Skyway.
- Dulles Greenway traffic increased by 8.2%.
- Growth projects in France despite political challenges.
- FX hedging program implemented for distribution support.
- Focus on resilience and new opportunities in OECD markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SGH Limited (SGH) ORDINARY FULLY PAID |
Industrials |
$19,007 |
BSL: BlueScope responds to revised takeover proposal
|
26 Feb 2026 8:25AM |
$47.790 |
$46.700 |
fallen by
2.28%
|
|
| BlueScope Steel Limited (BSL) ORDINARY FULLY PAID |
Materials |
$12,266 |
BlueScope responds to revised takeover proposal
|
26 Feb 2026 8:25AM |
$28.370 |
$28.000 |
fallen by
1.30%
|
|
BSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Kinterra offers a superior all-cash proposal.
- Premium over CAML proposal.
- Provides certainty of value with minimal conditionality.
- Significant shareholder influence by Kinterra.
- Benefits include liquidity and avoiding minority shareholder risks.
- Plans for board representation reflecting shareholding.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,964 |
2025 Annual Report and Appendix 4E
|
26 Feb 2026 8:25AM |
$4.840 |
$4.800 |
fallen by
0.83%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlas Arteria's total revenue for 2025 was AU$3,414.8 million, marking a 1.7% increase from 2024.
- The operating free cash flow for 2025 was AU$505.9 million, a 4.0% decline from the previous year.
- Net profit after tax for 2025 was AU$181.8 million, showing a 39.4% decrease compared to 2024.
- The proportional toll revenue increased by 9.4% to AU$2,012.3 million in 2025.
- The EBITDA margin for the year was 75.0%, slightly down from 75.1% in 2024.
- Atlas Arteria's total equity at the end of 2025 was AU$5,802.3 million, a decrease from AU$6,340.7 million in 2024.
- No new debt was issued during 2025, maintaining financial stability.
- The company reported substantial net debt reduction from AU$1,281.1 million to AU$1,254.4 million.
- Key investments include APRR, ADELAC, Warnow Tunnel, Chicago Skyway, and Dulles Greenway.
- Atlas Arteria’s key financial metrics are supported by strategic investments in its transport infrastructure projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ramsay Health Care Limited (RHC) ORDINARY FULLY PAID |
Health Care |
$9,942 |
2026 Calendar of Key Dates
|
26 Feb 2026 8:24AM |
$38.170 |
$43.070 |
risen by
12.84%
|
|
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,297 |
Dividend/Distribution - IEL
|
26 Feb 2026 8:24AM |
$4.590 |
$4.660 |
risen by
1.53%
|
|
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$32,784 |
Sigma Half Year Results ASX Release
|
26 Feb 2026 8:24AM |
$2.990 |
$2.840 |
fallen by
5.02%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Normalised EBIT increased by 18.7% to $582.9 million.
- Normalised NPAT increased by 19.2% to $392.0 million.
- Revenue grew by 14.9% to $5.5 billion.
- Australian CW branded store sales rose by 17.2%, with LFL sales up 15.0%.
- International growth saw retail network sales up 24.5%, LFL sales grew by 11.1%.
- Net debt decreased by $117.1 million to $635.1 million.
- The company declared an interim dividend of 2.0 cents per share.
- Over 400 new owned and exclusive products added, contributing to a 15.7% sales growth.
- The New Zealand business expanded to 70 stores with plans for further growth.
- International retail network sales exceeded $807 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Control Bionics Limited (CBL) ORDINARY FULLY PAID |
Health Care |
$25 |
Joint venture with NextLevel Assistive Technology
|
26 Feb 2026 8:24AM |
$0.060 |
$0.060 |
fallen by
0%
|
|
CBL - Price-sensitive ASX Announcement
Full Release
Key Points
- Control Bionics partners with NextLevel to expand iOS-based SGDs in the US.
- The partnership utilizes a capital-light, distributor-led model.
- Control Bionics to perform final assembly and distribution.
- NextLevel designs and manufactures device chassis and components.
- The US AAC market shifts towards tablet-based SGDs, particularly iOS.
- Control Bionics aligns strategy with existing distributor networks.
- The venture is designed to be revenue, profit, and cashflow accretive.
- NextLevel retains ownership of device intellectual property.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,297 |
H1 FY 26 Investor Presentation
|
26 Feb 2026 8:24AM |
$4.590 |
$4.660 |
risen by
1.53%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue down 6% compared to the previous corresponding period, with a focus on yield improvement.
- Student Placement volumes decreased by 25%, but yield increased by 15%.
- English Language Testing volumes dropped by 7%, but yield increased by 8%.
- The company is continuing with a transformation program aimed at a $25 million net reduction in the cost base for FY26.
- Adjusted EBIT for H1 FY26 was $87.5 million, marking a 14% decrease from the previous year.
- Net Profit After Tax (NPAT) for H1 FY26 was $48.6 million, a 25% decrease compared to the previous year.
- The company executed strong cost management, including a reduction of approximately 900 roles.
- IDP Education launched new student placement destinations and enhanced English Language Testing in new markets.
- The transformation program includes technology and AI investments to drive long-term growth.
- The financial outlook for FY26 includes upgraded Adjusted EBIT guidance, anticipating a challenging market environment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$32,784 |
Sigma Half Year Results Presentation
|
26 Feb 2026 8:24AM |
$2.990 |
$2.840 |
fallen by
5.02%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Sigma Healthcare reported a 14.9% increase in revenue for 1H26, reaching $5.5 billion.
- The company achieved a Normalised EBIT of $582.9 million, an 18.7% increase from the previous period.
- Normalised NPAT rose by 19.2% to $392.0 million.
- Sigma's Gross Profit Margin was stable at 18.3%, driven by favorable mix and supplier support.
- Operating expenses increased by 9.8%, with a focus on supporting domestic and international growth.
- Sigma opened 12 new international stores, bringing the total to 97, with international sales up 24.5%.
- The integration and synergy programs are on track with $13 million synergies realized so far.
- Domestic like-for-like sales in Chemist Warehouse branded stores increased by 15.0%.
- Sigma continues to expand its portfolio of owned and exclusive label products, contributing to revenue growth.
- The company's strategic priorities include expanding their pharmacy franchise and enhancing product differentiation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReadyTech Holdings Limited (RDY) ORDINARY FULLY PAID |
Information Technology |
$156 |
Appendix 4D and Interim Report
|
26 Feb 2026 8:24AM |
$1.730 |
$1.260 |
fallen by
27.17%
|
|
RDY - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities increased by 5.6% to $61.6 million.
- Loss after tax was reduced to $1.35 million, a 92.8% improvement from the previous period.
- No dividends were paid or declared during the period.
- Significant investment in research and development, comprising 29.5% of revenue.
- Challenges included market conditions, managed payroll churn, and a VETtrak cyber incident.
- The company is organised into Education and Work Pathways, Workforce Solutions, and Government and Justice segments.
- Deficiency in net current assets due to contract liabilities and employee benefits.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,297 |
H1 FY 26 Results Announcement
|
26 Feb 2026 8:24AM |
$4.590 |
$4.660 |
risen by
1.53%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for H1 FY26 was $462.2 million, a 6% decrease.
- Student Placement yield increased by 15%, Language Testing by 8%.
- Volumes declined for Student Placement by 25% and Language Testing by 7%.
- Adjusted EBIT was $87.5 million, a 14% decline.
- Transformation program aims for a $25 million cost base reduction in FY26.
- FY26 EBIT guidance upgraded to $120-$130 million.
- Interim dividend of 3.0 cents per share declared.
- Focus on digital and AI tools for efficiency and growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ramsay Health Care Limited (RHC) ORDINARY FULLY PAID |
Health Care |
$9,942 |
2026 Half Year Results Presentation
|
26 Feb 2026 8:24AM |
$38.170 |
$43.070 |
risen by
12.84%
|
|
RHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Ramsay Health Care Limited reported a 7.3% increase in Group underlying EBIT for the first half of the 2026 financial year.
- The Group's revenue grew by 9.7% compared to the first half of FY25, totaling $9.3 billion.
- Australian operations saw a 7.1% increase in EBIT, driven by increased activity and higher revenue indexation.
- Ramsay Santé's performance showed improvement with a 14.2% rise in underlying EBIT.
- The Group completed significant developments, including the Joondalup Private Hospital expansion.
- The Funding Group maintained a leverage ratio of 2.22x, within its target range.
- Capital expenditure for FY26 is expected to be between $755-795 million, focusing on procedural capacity in Australia.
- Ramsay UK faced challenges due to NHS budget constraints, but the company expects to benefit from additional future funding.
- Elysium's turnaround is progressing with cost reduction and site optimization efforts underway.
- Net financing expenses are forecasted to be $590-610 million for the fiscal year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,297 |
H1 FY26 Interim Financial Report
|
26 Feb 2026 8:24AM |
$4.590 |
$4.660 |
risen by
1.53%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY26 revenue fell by 5% to $462.2 million.
- Student placement revenue declined by 10%.
- Asia's revenue decreased by 12% due to lower volumes in Canada, US, and UK.
- Australasia experienced an 8% increase in revenue.
- Rest of World's revenue grew by 11%.
- Adjusted NPAT declined by 25% to $48.6 million.
- The company implemented a new accounting policy for revenue recognition.
- Corporate costs increased by 51% due to transformation initiatives.
- IDP maintained a consistent cash conversion rate of 59%.
- The transformation program aims for a more agile, technology-enabled organization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ramsay Health Care Limited (RHC) ORDINARY FULLY PAID |
Health Care |
$9,942 |
2026 Half Year Results Announcement
|
26 Feb 2026 8:23AM |
$38.170 |
$43.070 |
risen by
12.84%
|
|
RHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Ramsay reported a 253.2% increase in net profit after tax compared to the prior period.
- Underlying EBIT grew by 7.3%, and underlying NPAT increased by 8.1%.
- Strong performance in Australian operations with ongoing strategic transformation.
- Proposed acquisition of National Capital Private Hospital to expand in Canberra.
- Focus on high acuity cases and operational excellence in the UK amid NHS constraints.
- Mitigation measures implemented to address European funding headwinds.
- Declared a fully franked interim dividend of 42.5 cents per share.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$32,784 |
Half Year Accounts
|
26 Feb 2026 8:23AM |
$2.990 |
$2.840 |
fallen by
5.02%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for the half year was $5.5 billion with a significant increase from the previous year's $1.96 billion.
- Gross profit stood at $1,007.8 million, showing a substantial increase.
- Net profit after tax attributable to owners was $379.8 million, marking over 22% growth from the previous period.
- Basic and diluted earnings per share rose to 3.3 cents from 3.1 cents.
- The company declared an interim dividend of 2.0 cents per share, fully franked.
- Total equity of the group increased to $4.89 billion, up from $4.66 billion.
- The company operates in multiple regions including Australia, New Zealand, China, Ireland, and UAE.
- Total liabilities amounted to $3.85 billion, slightly up from $3.63 billion.
- The financial report confirms no contraventions of the Corporations Act 2001 or professional conduct codes.
- A merger with Chemist Warehouse was completed, incurring non-recurring costs for integration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Native Mineral Resources Holdings Limited (NMR) ORDINARY FULLY PAID |
Materials |
$100 |
NMR hits 14m @ 8.21g/t Au from 15m at Podosky, QLD
|
26 Feb 2026 8:23AM |
$0.090 |
$0.091 |
risen by
1.11%
|
|
NMR - Price-sensitive ASX Announcement
Full Release
Key Points
- NMR completed 11 out of 21 planned drill holes at Podosky.
- Significant gold intercept of 14m at 8.21g/t Au from 15m.
- Drilling confirms historic results and supports resource confidence.
- Joint venture with Haoma Mining to process ore at Blackjack.
- Proceeds from ore processing split 50-50 between NMR and Haoma.
- Program aims to convert Podosky resource into a mine-ready plan.
- Further drilling and exploration to expand resource definition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$13,581 |
Change of Director's Interest Notice - Anthony Hall
|
26 Feb 2026 8:23AM |
$116.230 |
$130.000 |
risen by
11.85%
|
|
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$1,725 |
Update - Notification of buy-back - MGH
|
26 Feb 2026 8:23AM |
$4.290 |
$4.780 |
risen by
11.42%
|
|
| Ramsay Health Care Limited (RHC) ORDINARY FULLY PAID |
Health Care |
$9,942 |
2026 Half Year Financial Report
|
26 Feb 2026 8:23AM |
$38.170 |
$43.070 |
risen by
12.84%
|
|
RHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax for the period was A$139.7 million.
- Revenue in Australia increased by 7.9%.
- European segment revenue rose by 11.5%.
- Total comprehensive income was A$122.4 million.
- Underlying EBIT and EBITDA increased across most regions.
- Ongoing performance improvement plans are expected to continue gaining traction.
- Focus on negotiating payor indexation in the UK for financial year 2026/27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID |
Health Care |
$43 |
Investor Webinar Tuesday 3 March @11.30 AEDT
|
26 Feb 2026 8:23AM |
$0.160 |
$0.150 |
fallen by
6.25%
|
|
| Control Bionics Limited (CBL) ORDINARY FULLY PAID |
Health Care |
$25 |
Half Yearly Report and Accounts
|
26 Feb 2026 8:23AM |
$0.060 |
$0.060 |
fallen by
0%
|
|
CBL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues from ordinary activities decreased by 26% to $2,820,044.
- Loss from ordinary activities after tax increased by 1201% to $3,609,172.
- No dividends were paid, recommended, or declared during the half-year.
- Net tangible assets per ordinary security were 0.73 cents as of 31 December 2025.
- Control Bionics Limited gained control over Neuro Elite Athletics, LLC, increasing its ownership to 100%.
- The financial statements were reviewed by auditors, with no contraventions of the auditor independence requirements of the Corporations Act 2001.
- Material uncertainty regarding going concern was noted, but the review conclusion was not modified.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cleanaway Waste Management Limited (CWY) ORDINARY FULLY PAID |
Industrials |
$5,712 |
Half Year Results ASX & Media Release and Presentation
|
26 Feb 2026 8:23AM |
$2.400 |
$2.550 |
risen by
6.25%
|
|
CWY - Price-sensitive ASX Announcement
Full Release
Key Points
- Cleanaway Waste Management reported a 13.0% increase in net revenue to $1,875.3 million for the half-year ending FY26.
- Underlying EBIT rose by 16.9% to $228.2 million, with an EBIT margin improvement of 40 basis points to 12.2%.
- The company's underlying NPAT increased by 17.8% to $109.7 million.
- Free Cash Flow decreased by 21.5% to $74.2 million due to acquisition and restructuring costs.
- A dividend of 3.35 cents per share was declared, up 19.6% from the previous year.
- EPSA rose by 18.2% to 5.2 cents, while underlying ROCE increased by 80 basis points to 9.4%.
- CWY's FY26 EBIT guidance was upgraded to between $480 million and $500 million.
- The company experienced strong results from acquisitions, with Contract Resources outperforming expectations.
- Positive outlook for solid waste services and environmental & technical solutions was noted.
- Capital expenditure for FY26 is expected to be approximately $415 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
